Page last updated: 2024-09-05

iclaprim and Group A Strep Infection

iclaprim has been researched along with Group A Strep Infection in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH	1
Hawser, S; Maher, K; Morrissey, I	1
Corey, GR; Stryjewski, ME	1

Reviews

1 review(s) available for iclaprim and Group A Strep Infection

Article	Year
New treatments for methicillin-resistant Staphylococcus aureus. Current opinion in critical care, 2009, Volume: 15, Issue:5 Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Daptomycin; Evidence-Based Medicine; Glycopeptides; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pyrimidines; Streptococcal Infections; Tigecycline	2009

Article

Year

New treatments for methicillin-resistant Staphylococcus aureus.

Current opinion in critical care, 2009, Volume: 15, Issue:5

Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Daptomycin; Evidence-Based Medicine; Glycopeptides; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pyrimidines; Streptococcal Infections; Tigecycline

2009

Trials

1 trial(s) available for iclaprim and Group A Strep Infection

Article	Year
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. International journal of antimicrobial agents, 2018, Volume: 52, Issue:2 Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin	2018

Article

Year

Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.

International journal of antimicrobial agents, 2018, Volume: 52, Issue:2

Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin

2018

Other Studies

1 other study(ies) available for iclaprim and Group A Strep Infection

Article	Year
Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae. The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:2 Topics: Anti-Bacterial Agents; Europe; Humans; Microbial Sensitivity Tests; Pyrimidines; Streptococcal Infections; Streptococcus agalactiae; Streptococcus pyogenes; United States	2009